Voloridge Investment Management
CLDX icon

Voloridge Investment Management’s Celldex Therapeutics CLDX Stock Holding History

Voloridge Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,308
Closed -$2.59M – 1164
2025
Q3 		$2.59M Buy
100,308
+79,335
+378% +$1.84M 0.01% 880
2025
Q2 		$427K Buy
+20,973
New +$408K ﹤0.01% 1094
2023
Q2 		– Sell
-6,916
Closed -$249K – 1384
2023
Q1 		$249K Buy
+6,916
New +$298K ﹤0.01% 1290
2022
Q1 		– Sell
-132,993
Closed -$5.14M – 1403
2021
Q4 		$5.14M Buy
132,993
+30,847
+30% +$1.34M 0.03% 720
2021
Q3 		$5.51M Buy
+102,146
New +$4.79M 0.04% 639
2015
Q2 		– Sell
-5,952
Closed -$2.49M – 312
2015
Q1 		$2.49M Buy
+5,952
New +$2.13M 0.12% 168
2014
Q2 		– Sell
-7,550
Closed -$2M – 90
2014
Q1 		$2M Buy
+7,550
New +$2.89M 0.28% 55

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Voloridge Investment Management's CLDX Position: Q4 2025 in Review

Voloridge Investment Management sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 100,308 shares — an estimated $2.59M sold.

Voloridge Investment Management first reported a position in CLDX in Q1 2014 and held it in 7 quarters. The position peaked at $5.51M in Q3 2021. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • Voloridge Investment Management reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 100,308 Celldex Therapeutics shares in Q4 2025, an estimated $2.59M.
  • Voloridge Investment Management first reported a position in Celldex Therapeutics in Q1 2014 and held it in 7 quarters.
  • Voloridge Investment Management's Celldex Therapeutics position peaked at $5.51M in Q3 2021.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Voloridge Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.